Careview Communications (OTCMKTS:CRVW) & Evaxion A/S (NASDAQ:EVAX) Head to Head Review

Careview Communications (OTCMKTS:CRVW) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Careview Communications and Evaxion A/S, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Careview Communications	0	0	0	0	0.00
Evaxion A/S	1	0	5	0	2.67

Evaxion A/S has a consensus price target of $11.00, suggesting a potential upside of 180.61%. Given Evaxion A/S’s stronger consensus rating and higher probable upside, analysts clearly believe Evaxion A/S is more favorable than Careview Communications.

Insider & Institutional Ownership

11.0% of Evaxion A/S shares are held by institutional investors. 63.9% of Careview Communications shares are held by insiders. Comparatively, 41.6% of Evaxion A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Careview Communications and Evaxion A/S”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Careview Communications	$9.02 million	2.59	-$3.20 million	($0.01)	-4.00
Evaxion A/S	$7.53 million	4.34	-$7.71 million	($1.47)	-2.67

Careview Communications has higher revenue and earnings than Evaxion A/S. Careview Communications is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Careview Communications has a beta of -0.78, meaning that its stock price is 178% less volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500.

Profitability

This table compares Careview Communications and Evaxion A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Careview Communications	-33.85%	N/A	-60.92%
Evaxion A/S	N/A	-73.56%	-37.45%

Summary

Evaxion A/S beats Careview Communications on 9 of the 14 factors compared between the two stocks.

About Careview Communications

CareView Communications, Inc. provides video monitoring solutions in the United States. Its products include CareView Patient Safety System, a video monitoring tool to improve the practice of nursing, create a better work environment, and make the patient's hospital stay more satisfying, which is used in hospitals, nursing homes, adult living centers, and outpatient care facilities; and CareView Connect, which provides resident monitoring products and services for the long- term care industry; an array of wearable and stationary buttons that allow a resident to summon help either for an emergency or assistance; a mobile app capable of delivering an alert to the caregiver and allows them document information around that alert; and alert management and monitoring system that provides a suite of hardware and software to facilitate a data-driven solution for alert management and monitoring. The company also offers Caregiver Platform that offers caregiver connect mobile application to provide a convenient and intuitive interface to capture critical workflows, such as acknowledging and documenting alert presses by the resident. In addition, it provides SitterView and TeleMedView that allows hospital staff to use CareView's video cameras to observe and communicate with patients remotely. CareView Communications, Inc. is based in Lewisville, Texas.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.